Showing 1761-1770 of 2123 results for "".
- Children with Spinal Muscular Atrophy Who Were Treated With Single-Dose Gene Therapy Continue Making Clinical Gainshttps://practicalneurology.com/news/children-with-spinal-muscular-atrophy-who-were-treated-with-single-dose-gene-therapy-continue-making-clinical-gains/2469026/Children treated with single-dose gene replacement therapy (Zolgensma; Avexis, Bannockburn, IL) for spinal muscular atrophy (SMA) continue meeting development milestones in the phase 3 SPR1NT clinical trial (NCT03505099). Treatment was
- Parkinson’s IQ + You Events Provide Support for All Affected by the Disorderhttps://practicalneurology.com/news/parkinsons-iq-you-events-support-provide-support-for-all-affected-by-the-disorder/2468940/A series of events titled Parkinson’s IQ + You will be taking place at locations across the US throughout 2019 and 2020. These events are designed to help people with Parkinson's disease (PD) and their care partners manage the effects of PD, learn about research, and connect with local
- Zolgensma Approved and Available to Treat All Types of Spinal Muscular Atrophy in Babies Under Age 2 Yearshttps://practicalneurology.com/news/zolgensma-approved-and-available-to-treat-all-types-of-spinal-muscular-atrophy-in-babies-under-age-2-years/2468911/The Food and Drug Administration (FDA) has approved onasemnogene abeparvovac-xioi (Zolgensma; Avexis, Bannockburn, IL) for the treatment of all types of spinal muscular atrophy (SMA) in children under age 2 years. Approved indications for onasemnogene, an SMN gene-replacement therapy, include all
- Young Blood Plasma for Parkinson's Diseasehttps://practicalneurology.com/news/young-blood-plasma-causes-neurological-improvement-in-parkinsons-disease-patients/2468880/Results of a clinical trial that administered blood plasma from donors, age 18 to 25 years, into individuals with Parkinson's disease resulted in significant improvements in neurologic assessments. After 3 months, patients showed improvements in motor
- Early Treatment of Clinically Isolated Syndrome With Interferon ß-1b Shows Benefit Over a 15-Year Periodhttps://practicalneurology.com/news/early-treatment-of-clinically-isolated-syndrome-with-interferon-1b-shows-benefit-over-a-15-year-period/2468814/Patients with clinically isolated syndrome (CIS) who were treated with interferon ß-1b (IFN) show long term benefits of early treatment (initiation within 2 years of diagnosis.) After 15 years, patients who were treated upon diagnosis of CIS (n = 161) or within 2 years of diagnosis (n = 100
- Alemtuzumab Effective for Treatment of MS Over 8 Years of Follow Uphttps://practicalneurology.com/news/alemtuzumab-effective-for-treatment-of-ms-over-8-years-of-follow-up/2468817/After 8 years of treatment with alemtuzumab (Lemtrada; Sanofi, Bridgewater, NJ), patients treated with 3 or more courses of the drug had an annualized relapse rate (ARR) of 0.18%, 85% of patients have been free of relapses, and 70% of patients had stable or improved scores on the Expanded Disabil
- Four-Year Clarity-AD Data Show Slower Clinical Decline with Leqembi Treatmenthttps://practicalneurology.com/news/four-year-clarity-ad-data-show-slower-clinical-decline-with-leqembi-treatment/2475914/According to new 48-month data from the Clarity-AD (NCT03887455) open-label extension (OLE) study presented at the 2025 meeting of the Alzheimer’s Association International Conference (AAIC), individuals with early Alzheimer disease (AD) who received continuous treatment with Leqembi (lecanemab-i
- Vagus Nerve Stimulation Paired With Rehabilitation Yields Sustained Upper Limb Recovery in Individuals With Strokehttps://practicalneurology.com/news/vagus-nerve-stimulation-paired-with-rehabilitation-yields-sustained-upper-limb-recovery-in-individuals-with-stroke/2474624/According to post hoc analysis of the VNS-REHAB clinical trial (NCT03131960), vagus nerve stimulation (VNS) paired with upper extremity (UE) rehabilitation showed significant improvements in UE impairment, activity, and quality-of-life (QoL) measures in individuals who experienced ischemic stroke
- The FDA Approved a New Oral, As-Needed Tablet for Acute Migraine Treatmenthttps://practicalneurology.com/news/the-fda-approved-a-new-oral-as-needed-tablet-for-acute-migraine-treatment/2473775/The Food and Drug Administration (FDA) has approved Symbravo (meloxicam and rizatriptan; Axsome Therapeutics, New York, NY) for the acute treatment of adults diagnosed with migraine with or without aura. Symbravo, previously known as AXS-07, is a single-dose, oral medication for use as-needed. Ax
- Uplizna Treatment for NMOSD Shows Sustained Clinical Benefit Over 4 Years According to Full N-MOmentum Datahttps://practicalneurology.com/news/uplizna-treatment-for-nmosd-shows-sustained-clinical-benefit-over-4-years-according-to-full-n-momentum-data/2470476/New end-of-study results from the N-MOmentum clinical trial (NCT02200770) which included data from the randomized controlled period and the open-label extension periods were published in The Lancet Neurology. According to the findings, long-term treatment with Uplizna (inebilizumab-cdon;